Can-Fite BioPharma Ltd. (CANF)Healthcare | Biotechnology | Ramat Gan, Israel | NYSE American
3.26 USD
+0.01
(0.308%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 3.17 -0.09 (-0.087%) ⇩ (July 13, 2026, 7:54 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:19 a.m. EDT
The immediate outlook is severely clouded by a massive 65% drop in the trailing twelve-month performance, leaving the stock trading significantly below its 200-day average despite a recent spike in volatility. While the company recently announced positive interim results for its psoriasis trial and a surge in pancreatic cancer data, these catalysts have failed to arrest the broader downtrend, which is now compounded by a reverse split that often signals distress. Fundamentally, the business is deteriorating rapidly with revenue contracting by nearly 44% year-over-year, negative operating margins of roughly 25%, and a lack of profitability. The balance sheet, while currently showing low debt relative to equity, is bleeding cash aggressively with free cash flow in the millions of dollars negative. There is no dividend to provide income, and the statistical models suggest a continued downward drift over the next month. The combination of shrinking revenues, burning cash, and a stock price that has lost 99.7% of its value over the last decade suggests the market has correctly identified a value trap where the business fundamentals are collapsing faster than any potential drug approval can save it. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.110596 |
| MSTL_55 | 0.143284 |
| MSTL | 0.172335 |
| AutoARIMA | 0.180655 |
| AutoETS | 0.181219 |
| MSTL_55_115 | 0.206747 |
| MSTL_115 | 0.228340 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 4.01 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.27 |
| Revenue per Share | 0.492 |
| Market Cap | 6,984,703 |
| Forward P/E | -12.07 |
| Beta | 0.02 |
| Website | https://www.canfite.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.842233 |
| Address1 | 26 Ben Gurion Street |
| All Time High | 28,380.0 |
| All Time Low | 2.56 |
| Ask | 3.28 |
| Ask Size | 100 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 8,582,060 |
| Average Daily Volume3 Month | 1,907,903 |
| Average Volume | 1,907,903 |
| Average Volume10Days | 8,582,060 |
| Beta | 0.023 |
| Bid | 3.23 |
| Bid Size | 600 |
| Book Value | 4.272 |
| City | Ramat Gan |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.26 |
| Current Ratio | 3.457 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.29 |
| Day Low | 3.15 |
| Debt To Equity | 1.27 |
| Display Name | Can-Fite BioPharma |
| Dividend Date | 1,557,446,400 |
| Earnings Timestamp End | 1,756,728,000 |
| Earnings Timestamp Start | 1,756,378,740 |
| Ebitda | -9,926,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.15 |
| Enterprise To Revenue | -3.665 |
| Enterprise Value | -1,484,298 |
| Eps Current Year | -0.68 |
| Eps Forward | -0.27 |
| Eps Trailing Twelve Months | -10.75 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 3 924 9378 |
| Fifty Day Average | 3.2472 |
| Fifty Day Average Change | 0.012799978 |
| Fifty Day Average Change Percent | 0.0039418507 |
| Fifty Two Week Change Percent | -84.2233 |
| Fifty Two Week High | 21.0 |
| Fifty Two Week High Change | -17.74 |
| Fifty Two Week High Change Percent | -0.8447619 |
| Fifty Two Week Low | 2.56 |
| Fifty Two Week Low Change | 0.70000005 |
| Fifty Two Week Low Change Percent | 0.27343753 |
| Fifty Two Week Range | 2.56 - 21.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,352,212,200,000 |
| Float Shares | 2,142,504 |
| Forward Eps | -0.27 |
| Forward P E | -12.074074 |
| Free Cashflow | -4,985,750 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 405,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.0655 |
| Implied Shares Outstanding | 2,142,547 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,767,571,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel. |
| Long Name | Can-Fite BioPharma Ltd. |
| Market | us_market |
| Market Cap | 6,984,703 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_676937 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -9,828,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 7,192,581 |
| Number Of Analyst Opinions | 1 |
| Open | 3.25 |
| Operating Cashflow | -8,949,000 |
| Operating Margins | -24.8867 |
| Payout Ratio | 0.0 |
| Phone | 972 3 924 1114 |
| Post Market Change | -0.08669996 |
| Post Market Change Percent | -2.659508 |
| Post Market Price | 3.1733 |
| Post Market Time | 1,783,986,848 |
| Previous Close | 3.25 |
| Price Eps Current Year | -4.7941175 |
| Price Hint | 4 |
| Price To Book | 0.7631087 |
| Price To Sales Trailing12 Months | 17.24618 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.127 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.307692 |
| Regular Market Day High | 3.29 |
| Regular Market Day Low | 3.15 |
| Regular Market Day Range | 3.15 - 3.29 |
| Regular Market Open | 3.25 |
| Regular Market Previous Close | 3.25 |
| Regular Market Price | 3.26 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 84,648 |
| Return On Assets | -0.66746 |
| Return On Equity | -1.78237 |
| Revenue Growth | -0.433 |
| Revenue Per Share | 0.492 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,142,547 |
| Shares Percent Shares Out | 0.15010001 |
| Shares Short | 321,495 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 67,832 |
| Short Name | Can-Fite Biopharma Ltd |
| Short Percent Of Float | 0.1509 |
| Short Ratio | 0.26 |
| Source Interval | 15 |
| Symbol | CANF |
| Target High Price | 8.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 8.0 |
| Target Median Price | 8.0 |
| Total Cash | 8,540,000 |
| Total Cash Per Share | 3.986 |
| Total Debt | 71,000 |
| Total Revenue | 405,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -10.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.2383 |
| Two Hundred Day Average Change | -1.9782999 |
| Two Hundred Day Average Change Percent | -0.37766066 |
| Type Disp | Equity |
| Volume | 84,648 |
| Website | https://www.canfite.com |
| Zip | 5,257,346 |